Fernando Cavalcanti

542 total citations
19 papers, 247 citations indexed

About

Fernando Cavalcanti is a scholar working on Molecular Biology, Rheumatology and Building and Construction. According to data from OpenAlex, Fernando Cavalcanti has authored 19 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Rheumatology and 4 papers in Building and Construction. Recurrent topics in Fernando Cavalcanti's work include Building Energy and Comfort Optimization (4 papers), Systemic Lupus Erythematosus Research (4 papers) and Epigenetics and DNA Methylation (3 papers). Fernando Cavalcanti is often cited by papers focused on Building Energy and Comfort Optimization (4 papers), Systemic Lupus Erythematosus Research (4 papers) and Epigenetics and DNA Methylation (3 papers). Fernando Cavalcanti collaborates with scholars based in Brazil, United States and Spain. Fernando Cavalcanti's co-authors include Julián Garcı́a-Rafanell, J Forn, Alberto Fernández de Arriba, Andrés Alonso, Yolanda Bayón, Ana Miralles-Marco, Manuel Merlos, P A Bacon, Daniel Wojdyla and David Rotllant and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Fernando Cavalcanti

16 papers receiving 238 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fernando Cavalcanti Brazil 9 87 83 59 30 23 19 247
Guohong Gao China 8 170 2.0× 32 0.4× 35 0.6× 17 0.6× 41 1.8× 13 337
Isabella Marinò Italy 5 87 1.0× 107 1.3× 262 4.4× 64 2.1× 61 2.7× 6 384
Sofia Töyrä Silfverswärd Sweden 11 105 1.2× 84 1.0× 128 2.2× 30 1.0× 21 0.9× 25 341
Kristin G. Ardlie United States 7 77 0.9× 56 0.7× 77 1.3× 16 0.5× 14 0.6× 7 268
Sébastien Lévesque Canada 12 179 2.1× 48 0.6× 32 0.5× 23 0.8× 13 0.6× 20 336
Nicola Carboni Italy 8 180 2.1× 30 0.4× 13 0.2× 34 1.1× 11 0.5× 14 319
Amandine Perrin Germany 8 39 0.4× 55 0.7× 21 0.4× 29 1.0× 56 2.4× 21 295
Kimberly M. Winges United States 9 62 0.7× 50 0.6× 70 1.2× 7 0.2× 8 0.3× 14 353
Azza Ismail United Kingdom 10 65 0.7× 15 0.2× 24 0.4× 6 0.2× 60 2.6× 16 268
Naomichi Iwai Japan 13 113 1.3× 26 0.3× 15 0.3× 11 0.4× 6 0.3× 38 384

Countries citing papers authored by Fernando Cavalcanti

Since Specialization
Citations

This map shows the geographic impact of Fernando Cavalcanti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Cavalcanti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Cavalcanti more than expected).

Fields of papers citing papers by Fernando Cavalcanti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Cavalcanti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Cavalcanti. The network helps show where Fernando Cavalcanti may publish in the future.

Co-authorship network of co-authors of Fernando Cavalcanti

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Cavalcanti. A scholar is included among the top collaborators of Fernando Cavalcanti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Cavalcanti. Fernando Cavalcanti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Cavalcanti, Fernando, Elena González‐Rey, Mario Delgado, et al.. (2022). Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 14(7). 1420–1420. 6 indexed citations
2.
Cavalcanti, Fernando. (2022). ARQSOLAR: Uma ferramenta Android para o ensino-aprendizagem das cartas solares. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas). 7. 47–47.
3.
Maes, Tamara, Cristina Mascaró, David Rotllant, et al.. (2020). Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. PLoS ONE. 15(5). e0233468–e0233468. 44 indexed citations
4.
Cavalcanti, Fernando, et al.. (2020). Analysis of the potential use of Trombe walls in Brazil: design recommendations. SHILAP Revista de lepidopterología. 5. 4–4. 1 indexed citations
5.
Cavalcanti, Fernando. (2020). Impacto da absortância e transmitância das fachadas na eficiência energética e conforto térmico para habitação de interesse social. Paranoá cadernos de arquitetura e urbanismo. 2 indexed citations
6.
Cavalcanti, Fernando, et al.. (2020). Influência do peitoril de janelas na luz natural e visão de céu em enfermarias. SHILAP Revista de lepidopterología. 11. e020009–e020009. 1 indexed citations
7.
Rivers, Angela, Kestis Vaitkus, Ramasamy Jagadeeswaran, et al.. (2018). Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. Experimental Hematology. 67. 60–64.e2. 18 indexed citations
8.
Rivers, Angela, Kestis Vaitkus, Ramasamy Jagadeeswaran, et al.. (2017). Oral Administration of the LSD1 Inhibitor OG-S1335 Increases Fetal Hemoglobin in Humanized Transgenic Sickle Cell Disease Mice and in Baboons. Blood. 130. 356–356. 1 indexed citations
9.
Pons‐Estel, Bernardo A., Daniel Wojdyla, Graciela S. Alarcón, et al.. (2016). CE-45 Baseline factors predictive of the occurrence of neuropsychiatric damage accrual in latin american patients with systemic lupus erythematosus. A71.2–A72. 1 indexed citations
10.
11.
Maes, Tamara, Cristina Mascaró, David Rotllant, et al.. (2016). P4‐404: Ory‐2001: An Epigenetic Drug for the Treatment of Cognition Defects in Alzheimer’S Disease and Other Neurodegenerative Disorders. Alzheimer s & Dementia. 12(7S_Part_24). 8 indexed citations
12.
Pons‐Estel, Guillermo, Graciela S. Alarcón, Daniel Wojdyla, et al.. (2012). Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Lara D. Veeken. 51(7). 1293–1298. 35 indexed citations
13.
Pons‐Estel, Guillermo, Verónica Saurit, Alarcón Gs, et al.. (2012). The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort. Lupus. 21(13). 1397–1404. 23 indexed citations
14.
Marques, Cláudia Diniz Lopes, et al.. (2005). Doença de Castleman mimetizando doença de Still do adulto. Revista Brasileira de Reumatologia. 45(5). 331–334. 1 indexed citations
15.
Cavalcanti, Fernando. (2005). Terapia com células-tronco: esperança ou novo marketing?. Revista Brasileira de Reumatologia. 45(4).
16.
Arriba, Alberto Fernández de, Fernando Cavalcanti, Ana Miralles-Marco, et al.. (1999). Inhibition of Cyclooxygenase-2 Expression by 4-Trifluoromethyl Derivatives of Salicylate, Triflusal, and Its Deacetylated Metabolite, 2-Hydroxy-4-trifluoromethylbenzoic Acid. Molecular Pharmacology. 55(4). 753–760. 45 indexed citations
17.
Arriba, Alberto Fernández de, et al.. (1996). In vitro pharmacological characterization of a new selective angiotensin AT1 receptor antagonist, UR-7280. European Journal of Pharmacology. 318(2-3). 341–347. 30 indexed citations
18.
Johnson, Angela E., Fernando Cavalcanti, Caroline Gordon, et al.. (1994). Cross-Sectional Analysis of the Differences Between Patients with Systemic Lupus Erythematosus in England, Brazil and Sweden. Lupus. 3(6). 501–506. 22 indexed citations
19.
Alexander, Graham J., P A Bacon, Fernando Cavalcanti, David R. Blake, & Nicolas Hall. (1984). LOW DENSITY LYMPHOCYTES: THEIR RELATIONSHIP TO DISEASE ACTIVITY AND TO ANTIRHEUMATIC THERAPY. Lara D. Veeken. 23(1). 6–14. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guohong Gao Breakdown of academic impact, for papers by Isabella Marinò Breakdown of academic impact, for papers by Sofia Töyrä Silfverswärd Breakdown of academic impact, for papers by Kristin G. Ardlie Breakdown of academic impact, for papers by Sébastien Lévesque Breakdown of academic impact, for papers by Nicola Carboni Breakdown of academic impact, for papers by Amandine Perrin Breakdown of academic impact, for papers by Kimberly M. Winges Breakdown of academic impact, for papers by Azza Ismail Breakdown of academic impact, for papers by Naomichi Iwai
Rankless by CCL
2026